Home Biosimilar Antibodies Immunology & Inflammation PD-1/PD-L1 Atezolizumab (anti-PD-L1)
For research use only. Not for use in humans.

Atezolizumab (anti-PD-L1)

Synonyms: MPDL3280A

Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

Atezolizumab (anti-PD-L1) Chemical Structure

Click to purchase the isotype control of Atezolizumab (anti-PD-L1)

75 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 6.09 mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 14
BMS-1 13
BMS-202 28
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 5
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
Features
Human IgG1
Targets/IC50/Ki
hPD-L1
(Cell-free assay)
0.4 nM(Kd)
In vitro

Treatment with single agent atezolizumab exerted a moderate anti-proliferative effect with ~ 30% cell death across all models.
Cell Research

A MTT cell proliferation assays in human spheroids (A) or EPCAM+/CD45- cells (b), untreated or treated with selumetinib, atezolizumab, avelumab, or their combinations.
In vivo

when dual drug–loaded, core-shell nanoparticles (DLTPT) is used in combination with anti PD-L1, the tumor growth is inhibited, which induced immune response against tumor metastasis.
Animal Research

Animal Models: 4T1 tumor–bearing BALB/c mice
Dosages: 2.5 or 5 mg/kg
Administration: i.v.
Reference:[2]
References

Product Details

CAS No. 1380723-44-3
Isotype Human IgG1
Source CHO cells
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05620771 RECRUITING Drug: Y90 + Atezolizumab and Bevacizumab|Drug: Y90 + TKI Hepatocellular Carcinoma Northwestern University 2022-11-30 PHASE2
NCT04817956 RECRUITING Drug: Atezolizumab Cancer Metastatic Oslo University Hospital 2021-04-01 PHASE2
NCT07770100 NOT_YET_RECRUITING Drug: Pembrolizumab|Drug: Nivolumab|Drug: Atezolizumab|Drug: Head and Neck Cancer; Non-Small Cell Lung Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer (GC) Mark Bernard 2026-10-01 PHASE2
NCT05862285 RECRUITING Drug: Ipatasertib|Drug: Tiragolumab|Drug: Atezolizumab|Drug: Cancer Hoffmann-La Roche 2023-06-01 PHASE3
NCT04589845 ACTIVE_NOT_RECRUITING Drug: Entrectinib|Drug: Entrectinib|Drug: Alectinib|Drug: At Solid Tumors Hoffmann-La Roche 2021-01-18 PHASE2
NCT05468359 RECRUITING Drug: Atezolizumab|Drug: Sorafenib|Drug: Bevacizumab|Drug: C Refractory Solid Tumor; Hepatocellular Carcinoma; Malignant Solid Tumor; Pediatric Cancer; Pediatric Solid Tumor; Fibrolamellar Carcinoma St. Jude Children's Research Hospital 2022-11-07 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-05-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.